Compare LI & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LI | NBIX |
|---|---|---|
| Founded | 2015 | 1992 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.8B | 13.9B |
| IPO Year | N/A | 1996 |
| Metric | LI | NBIX |
|---|---|---|
| Price | $17.35 | $129.78 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 22 |
| Target Price | $20.46 | ★ $175.27 |
| AVG Volume (30 Days) | ★ 2.4M | 1.2M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.95 |
| EPS | N/A | ★ 4.67 |
| Revenue | N/A | ★ $161,626,000.00 |
| Revenue This Year | N/A | $22.85 |
| Revenue Next Year | $19.97 | $9.99 |
| P/E Ratio | $29.50 | ★ $27.38 |
| Revenue Growth | N/A | ★ 977.51 |
| 52 Week Low | $15.71 | $84.23 |
| 52 Week High | $32.03 | $160.18 |
| Indicator | LI | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 45.45 | 44.86 |
| Support Level | $16.25 | $129.17 |
| Resistance Level | $17.65 | $136.74 |
| Average True Range (ATR) | 0.44 | 3.01 |
| MACD | -0.05 | 0.10 |
| Stochastic Oscillator | 33.89 | 28.93 |
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 500,000 NEVs in 2024, accounting for about 4% of China's passenger new energy vehicle market. Beyond Li One, the company expands its product line, including both BEVs and PHEVs, to target a broader consumer base.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.